We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

75 hedge funds and large institutions have $119M invested in Stemline Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 15

104% more call options, than puts

Call options by funds: $2.41M | Put options by funds: $1.18M

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

14% more capital invested

Capital invested by funds: $104M → $119M (+$14.7M)

1% more funds holding

Funds holding: 74 → 75 (+1)

Holders
75
Holders Change
+1
Holders Change %
+1.35%
% of All Funds
1.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
33
Reduced
15
Closed
14
Calls
$2.41M
Puts
$1.18M
Net Calls
+$1.23M
Net Calls Change
+$881K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.69M
3
FCM
Farallon Capital Management
California
+$8.29M
4
Axa
Axa
France
+$3.96M
5
IBT
International Biotechnology Trust
United Kingdom
+$3.01M

Top Sellers

Rank Fund Capital Flow
1
CS
Candriam SCA
Luxembourg
-$2.61M
2
Invesco
Invesco
Georgia
-$1.81M
3
BIM
Bogle Investment Management
Massachusetts
-$1.01M
4
VMI
VHCP Management II
New York
-$801K
5
Renaissance Technologies
Renaissance Technologies
New York
-$701K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$648K +$62.2K +6,824 +10%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$589K -$98.6K -10,820 -14%
HT
28
HAP Trading
New York
$559K +$596K +65,387 New
TCIM
29
TIAA CREF Investment Management
New York
$532K +$71.9K +7,888 +15%
PVI
30
Pura Vida Investments
New York
$513K +$547K +60,000 New
TI
31
Trexquant Investment
Connecticut
$490K +$522K +57,311 New
Ameriprise
32
Ameriprise
Minnesota
$375K +$31.9K +3,500 +9%
TA
33
Teachers Advisors
New York
$366K +$69.8K +7,661 +22%
California State Teachers Retirement System (CalSTRS)
34
California State Teachers Retirement System (CalSTRS)
California
$360K +$67.4K +7,400 +21%
Charles Schwab
35
Charles Schwab
California
$344K +$129K +14,200 +55%
ORI
36
Oak Ridge Investments
Illinois
$310K +$18.7K +2,055 +6%
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$307K +$43K +4,716 +15%
ARTA
38
A.R.T. Advisors
New York
$299K +$319K +35,038 New
Morgan Stanley
39
Morgan Stanley
New York
$274K -$162K -17,823 -36%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$266K – – –
UBS Group
41
UBS Group
Switzerland
$230K +$139K +15,232 +130%
CD
42
Carl Domino
Florida
$222K – – –
AQR Capital Management
43
AQR Capital Management
Connecticut
$219K +$233K +25,562 New
SIP
44
Stoneridge Investment Partners
Pennsylvania
$217K -$76.6K -8,402 -25%
TI
45
Telemetry Investments
New York
$201K -$13.5K -1,486 -6%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$197K +$35.1K +3,847 +20%
OPPM
47
Opus Point Partners Management
New York
$176K +$188K +20,595 New
Jacobs Levy Equity Management
48
Jacobs Levy Equity Management
New Jersey
$160K -$57K -6,254 -25%
PAM
49
Paradigm Asset Management
New York
$137K -$62K -6,800 -30%
Zurich Cantonal Bank
50
Zurich Cantonal Bank
Switzerland
$120K +$128K +14,000 New
1
2
3 4

STML Hedge Fund Activity: Q1 2017 in Review

75 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2017, worth a combined $119M — up 14% from $104M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new STML positions and 14 closed out — a net gain of 6 holders — while 33 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $11M. The largest seller was Candriam SCA, exiting entirely with an estimated $2.61M sold.

  • 75 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2017, up from 74 in Q4 2016.
  • Funds reported $119M of Stemline Therapeutics, Inc. stock for Q1 2017, up 14% quarter-over-quarter.
  • 20 funds opened new Stemline Therapeutics, Inc. positions in Q1 2017 and 14 closed out, a net change of +6 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $11M added.
  • The largest Stemline Therapeutics, Inc. seller in Q1 2017 was Candriam SCA, an estimated $2.61M sold.

Based on aggregated 13F filings for Q1 2017.